Afatinib
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Afatinib: From EGFR-Driven Cancers to HER2-Positive Breast Carcinoma
One-Sentence Summary
Afatinib is an oral, irreversible ErbB family blocker (EGFR/HER2/HER4) that is marketed in Singapore as Giotrif film-coated tablets. The TxGNN model predicts it may be effective for HER2-positive breast carcinoma, with 4 clinical trials (all Phase 2) and 19 publications currently supporting this direction, but clinical benefit has been limited in head-to-head comparisons.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the Singapore licence records contain no indication text) |
| Predicted New Indication | HER2 positive breast carcinoma |
| TxGNN Prediction Score | 98.65% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on the published literature, afatinib is an irreversible ErbB family blocker that covalently binds the kinase domains of EGFR, HER2 and HER4. HER2 is the driver of this breast cancer subtype, so the drug directly targets the disease biology.
Resistance to trastuzumab may be mediated by other ErbB family members, which is the rationale for broader ErbB blockade with afatinib. Four Phase 2 trials and the published LUX-Breast programme support biological activity, particularly in patients who progressed on trastuzumab or lapatinib and in patients with brain metastases.
Clinical benefit has been limited, however. In LUX-Breast 1 (a Phase 3 trial), afatinib plus vinorelbine did not improve outcomes over trastuzumab plus vinorelbine, and tolerability problems (diarrhoea, rash) were notable. Any further use would be niche, for example in brain metastases or after trastuzumab failure.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01594177 | Phase 2 | Completed | 65 | Afatinib plus trastuzumab as dual-blockade neoadjuvant therapy alongside taxane-anthracycline chemotherapy in HER2+ breast cancer |
| NCT01441596 | Phase 2 | Completed | 121 | LUX-Breast 3: afatinib alone or with vinorelbine vs investigator's choice in HER2+ patients with progressive brain metastases |
| NCT00431067 | Phase 2 | Completed | 41 | Single-agent afatinib (BIBW 2992) in HER2+ metastatic breast cancer after trastuzumab failure; modest activity |
| NCT04158947 | Phase 2 | Unknown | 130 | Afatinib plus T-DM1 vs T-DM1 alone in HER2+ breast cancer with refractory brain metastases; results unlikely to be available |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26822398 | 2016 | RCT (Phase 3) | Lancet Oncol | LUX-Breast 1: afatinib plus vinorelbine vs trastuzumab plus vinorelbine after one prior trastuzumab treatment |
| 35138529 | 2022 | RCT (Phase 2) | Breast Cancer Res Treat | LUX-Breast 2: afatinib alone and with vinorelbine or paclitaxel after failure of prior HER2-targeted therapy |
| 35653982 | 2022 | Meta-analysis | ESMO Open | Systematic review of tyrosine kinase inhibitors in HER2+ breast cancer with brain metastases |
| 25537159 | 2015 | Phase 2 RCT | Clin Breast Cancer | Neoadjuvant afatinib vs trastuzumab vs lapatinib in locally advanced HER2+ breast cancer |
| 29772459 | 2018 | Review | Cancer Treat Rev | Tyrosine kinase inhibitors for brain metastases in HER2+ breast cancer |
| 24870559 | 2014 | Review | Expert Opin Investig Drugs | Afatinib in breast cancer; activity still under evaluation |
| 34280871 | 2021 | Review | Eur J Cancer | Role of tyrosine kinase inhibitors in HER2+ metastatic breast cancer |
| 30062574 | 2019 | Preclinical | Invest New Drugs | Adding afatinib and other TKIs to trastuzumab and pertuzumab enhanced anti-proliferative effects in HER2+ cell lines |
| 23692263 | 2013 | Review | Curr Med Res Opin | Cardiotoxicity of novel HER2-targeted therapies |
| 24127221 | 2013 | Review | Drugs | Optimal sequencing of anti-HER2 therapy across the disease course |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14460P | GIOTRIF FILM-COATED TABLETS 20MG | Film-coated tablet | Not recorded |
| SIN14461P | GIOTRIF FILM-COATED TABLETS 30MG | Film-coated tablet | Not recorded |
| SIN14462P | GIOTRIF FILM-COATED TABLETS 40MG | Film-coated tablet | Not recorded |
All three licences are valid single-ingredient products from Boehringer Ingelheim Pharma GmbH & Co. KG.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (irreversible ErbB family tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert; thrombocytopenia has been reported as an adverse event, mainly in combination with chemotherapy in Phase 1 studies |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC, liver and renal function; monitor for diarrhoea and rash, which were notable in breast cancer trials |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 100 interactions were identified, and the main ones are listed below.
- Major: aminolevulinic acid.
- Moderate: clarithromycin, erythromycin, ketoconazole, cobicistat, tacrolimus, dexamethasone, abiraterone, alpelisib, ivacaftor, quinine, and others.
- Minor: prucalopride.
- Other tolerability signals from the literature: diarrhoea and rash were notable in breast cancer trials, and the cardiotoxicity of HER2-targeted therapies is a recognised class concern.
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for these.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Afatinib directly targets HER2, and several completed Phase 2 trials plus the LUX-Breast programme show biological activity. However, the Phase 3 comparison with trastuzumab did not show an advantage and tolerability was a concern, so any use should be confined to a narrow setting such as brain metastases or after trastuzumab failure.
To proceed, the following is needed:
- The HSA package insert, to confirm warnings, contraindications and approved indications (currently missing)
- Detailed mechanism of action data (MOA)
- A defined target population (for example HER2+ with brain metastases or post-trastuzumab) and a plan for managing diarrhoea and rash
- Review of the DDI list, particularly the major interaction with aminolevulinic acid and CYP/P-gp-related moderate interactions
Other predicted indications (not recommended at this time): The remaining top-ranked predictions are weaker. Progesterone-receptor positive and negative breast cancer are subsets of the HER2+ evidence and not independent signals. Multiple endocrine neoplasia has only non-specific basket trials. Thrombocytopenia most likely reflects an adverse-event association rather than a therapeutic effect. The other platelet-related predictions and the normal-like and luminal breast subtypes are prediction-only or indirect and should be on hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.